GlassScriptPhysician profile
Beth A Loss
NPI 1831159797
$1,851.31
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $83.15 · 2021: $449 · 2022: $188.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $303.59 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $252.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $210.00 | 2019-2021 | |
| Amgen INC. | $163.61 | 2019-2021 | |
| Si-Bone, INC. | $142.20 | 2019 | |
| Medtronic Vascular, INC. | $131.00 | 2019 | |
| Abbvie INC. | $110.64 | 2021 | |
| Allergan, INC. | $100.67 | 2019 | |
| Glaxosmithkline, LLC. | $99.99 | 2019 | |
| Novo Nordisk INC | $97.64 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.58 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.02 | 2019 | |
| Optinose US, INC. | $68.79 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Loss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.